Dear Sir/Madam,

We would like to kindly inform you that the journal “GUJARAT CANCER SOCIETY RESEARCH JOURNAL (ISSN: 2320-1150)” has passed the evaluation process positively and is indexed in the ICI Journals Master List database for 2021. From now on, the Editorial Staff and Publisher may use this information in their external communication.

Based on the information submitted in the evaluation and the analysis of the issues of the journal from 2021, Index Copernicus Experts calculated your Index Copernicus Value (ICV) for 2021.

ICV 2021 = 58.17

The ICV for 2021 is visible on the full list of indexed journals at ICI Journals Master List 2021, [https://journals.indexcopernicus.com/search/formjm](https://journals.indexcopernicus.com/search/formjm) and in Journal’s Passport [https://journals.indexcopernicus.com/search/details?id=32195&lang=p](https://journals.indexcopernicus.com/search/details?id=32195&lang=p)

---

**DISCLAIMER**

1. The information and opinions published in this Journal reflect the views of the authors and not of the Journal, or its Editorial Board or the Publisher.
2. Responsibility for accuracy of the contents, any injury/damage/libelous statement towards persons or property or privacy rights shall be of the authors of the article.
3. Publication of an advertisement in this Journal does not constitute on the part of the Publisher or the Organization a guarantee or endorsement of the quality or value of the advertised product or services described therein or of any of the representations or the claims made by the advertisers with respect to such products or services.
Editorial
• The Role of Pathology in the Era of Personalized (Precision) Medicine: Shifting Sands of Time 1
  Trivedi Priti, Paul Thayakaran Immanuel

Oration Synopses
• Shri Madanmohan Ramanlal GCRI Luminary Oration Award 4
  Dr. Shakuntala V. Shah

• Dr. Shilin N. Shukla Medical Oncology Oration Award 5
  Dr. Sandip A. Shah

I. Original Article
• Diagnostic Value of Neutrophil Leukocyte Ratio and Platelet Lymphocyte Ratio to Differentiate Adnexal Masses as Benign or Malignant in the Preoperative Period 7
  Hantodkar Rujuta, Patel Bijal, Dave Pariseema, Parekh Chetana, Kar Bijoy

II. BrainWaves
• It’s Better to Be Alive While Dying than Dead While Living 10
  Trivedi Maharshi

III. Case Reports
• Squamous Cell Carcinoma of External Auditory Canal Metastasis to CSF: A Diagnostic Conundrum 12
  BR Nagarjun, Patel Trupti, Shah Majal, Dhandapani Kartik

• Primary Pleomorphic Liposarcoma of Bone: A Rare Tumor in Unusual Location with Review of Literature 15
  Vanik Sangita A, Gami Amisha, Kaur Kanwalpreet, Trivedi Priti

• Recurrence Developing 21 Years After Treatment of Breast Cancer 19
  Vagashiyaa Vidhi, Mehta Maitrik, Parikh Ankita, Shah Sonal, Suryanarayan U

IV. Appendix
• List - Presentations at Clinical Meetings 21

V. About the Journal & Instructions to Author 22

VI. Contributor’s Form 26

VII. Guidelines for Reviewers 27

VIII. Organizational Information
Detection of Genetic Alterations in Cancer by Fully Automated Next Generation Sequencer at Cancer Biology Department, GCRI 28
  Mandalia Toral, Vora Hemangini

Address for correspondence:
The Editors, Gujarat Cancer Society Research Journal GCS Journal Office, Research Wing, The Gujarat Cancer and Research Institute Asarwa, Ahmedabad 380016 Gujarat, India gcsjournal2012@gmail.com gcsjournal2012@gcriindia.org

(Formerly Published as GCS Research Bulletin)
The Role of Pathology in the Era of Personalized (Precision) Medicine: Shifting Sands of Time

Trivedi Priti, Paul Thayakaran Immanuel
Practicing Professor & Head of Department, Resident
Department of Oncopathology,
The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, Gujarat
Corresponding author: priti.trivedi@gcriindia.org
https://orcid.org/0000-0003-1895-389X

Introduction
Diagnostic pathology in the early 19th century was restricted to postmortem assessment wherein the effects of disease and its sequelae were looked out for, described, and documented and thereby helping the medical personnel in identifying the disease in the clinic. However with the advent of light microscopy in the latter half of the 19th century, thanks to Rudolf Virchow (1821-1902) who was aptly named as “Father of modern pathology” there was a paradigm shift in the field of pathology where the pathologic diagnosis became an intrinsic component in patient management dictating what intervention would the patient need.

Detailed morphologic assessment and evaluation of a tumor under a light microscope led to the characterization of diverse types and morphology of a tumor setting in motion for the microscopic classification systems for several diseases. The classification especially of neoplastic tumors not only helped the pathologists to have a unified nomenclature but also created a better understanding of the diagnosis amongst the treating clinicians.

Just when the widespread knowledge of neoplastic pathology with well-defined classifications were doing round there was a major transpose in the field of pathology in the latter half of 20th century with the advent of immunohistochemistry which was of immense help especially in diagnosing the poorly differentiated neoplasms and more importantly immunohistochemistry served as a cornerstone in the sub classification of lymphoma which previously was solely dependent on morphology alone.

Twentieth century witnessed a major medical field awakening with many dramatic discoveries in cellular and molecular pathways. The knowledge accrued was extrapolated to improve disease diagnostics and prognostics. Many immunomarkers came into the fore which helped both in diagnosis and therapeutic. New genetic and molecular alterations were discovered which conferred differential prognosis for a single morphological disease entity highlighting the need and paving the way for the dawn of molecular classification of tumors.

The shifting sands of time in the field of pathology has propelled the pathologist out of a laboratory and commissioned the pathologist to the patient’s bedside making pathology an integral part in the multidisciplinary/ tumor board meetings providing pertinent diagnostic, therapeutic and prognostic information where decisions are made for optimal management on a case-to-case basis paving the way for personalized (precision) medicine. (Figure 1)

Figure 1: A proposed algorithm for the pathology role in personalized (precision) medicine.

Precision Medicine and Pathology
Gone is the idea of one-size –fits-all approach because history and studies have proven that there are innumerable variables predicting the patient’s response to therapy and it markedly differs from one person to person. Personalized (precision) medicine is currently the standard of care in all cancers. Precision medicine is an innovative approach of tailoring disease treatment considering an individual’s genetic make-up, environment and lifestyle. Precision medicine takes help of massive parallel sequencing, high throughput technologies to enable detection of minute changes at different molecular levels (DNA, RNA, protein). DNA/RNA sequencing, tissue
microarray technology, mass spectrophotometry, comparative genomic hybridization and digital polymerase chain reaction are the platforms used in arriving at the best plan of treatment.

When a tissue or specimen arrives to pathology lab for tissue diagnosis it is triaged based on the preliminary diagnosis and is segregated into different forms of preservation for appropriate downstream applications. The pathologist examines the tissue and a histologic diagnosis made keeping in mind at the same to assess the tissue for tumor quantity and tumor adequacy for further molecular tests. The pathologist interprets the findings in concert with molecular biologist and reports the relevant details.

The clinician accordingly plans the management of the patient based on the integrated pathology report which now includes morphological, immunohistochemical and molecular report. Integrated pathology report is now routinely practiced in many subspecialties in pathology including neuropathology, thoracic pathology and soft tissue pathology to name a few.

Role of Pathology in Patient Clinic

Tumor board meets or multidisciplinary meeting is an integral component of oncologic patient management where the pathologist, radiologist, medical and surgical oncologist come in concert and discuss the diagnosis and plan the management of the patient which aids in optimal treatment decisions.

From an oncologic perspective, preliminary patient management is based on the small tissue biopsy. The surgical management and the neoadjuvant chemotherapy are based on the type and the grade of tumor coupled with informative immunohistochemical markers and molecular tests wherever pertinent. Hormonal receptor status and HER2 amplification status in breast cancer remains a major cornerstone of treatment decision and selection of therapy. Identification of alterations in EGFR, ALK, ROS gene mutations in lung cancer aids the clinician in selecting the targeted drugs for initial management. Few patients have progressive disease which might indicate underlying resistance to the targeted drugs where a repeat biopsy from the involved site can identify concomitantly the tumor and the resistant mutation it has accrued, for example identification of T790M mutation in patients with EGFR mutated lung cancer helps the clinician to escalate the therapy to Osimertinib which is effective in these patients.

Recently predictive biomarkers which identify whether a patient will respond to a particular therapy have become a norm for certain tumors like HER2 receptor status in breast cancer which is a prototype. Some aggressive or poorly differentiated cancers where the patient is not responding to conventional treatment modalities, additional molecular markers or mutations are actively hunted for in a tumor sample which can aid in the addition of drugs which can prolong patient survival. Immune checkpoint inhibitors can be utilized in the therapy by performing immunohistochemistry and looking at the PD1 receptor status in the tumor infiltrating lymphocytes and the PDL1 receptor status in the tumor cells.

The time has come for most of the tumors which were previously classified based solely on morphology to transit into the era of molecular medicine where most of the tumor classification systems currently are on the road to adapting molecular classifications. A classic example would be the lymphoma and leukemia classification which initially was based on morphology alone (Rappaport classification, 1966) followed by addition of immunohistochemistry (Kiel classification, 1975), addition of molecular and clinical profile (Revised European America Lymphoma – REAL classification, 1994) to the current WHO classification which has undergone subsequent editions.

Molecular classification of breast cancer has been well established in the past decade with recent consolidation of molecular classification of endometrial cancer and urothelial cancer. Molecular classification of sinonasal cancers are still in the pipeline. It is now well known that the molecular subgroups have divergent disease biology which might dictate diverse treatment algorithms. The pathologist in the clinic is expected to give not only an integrated report but also provide a holistic report based on the current advances in oncological practice.

Role of Pathology in Research

The field of oncopathology witnesses new tumor entities by the day, thanks to the advent of molecular diagnostics. A new tumor/entity is birthed when a pathologist comes across a tumor which does not follow the book. When a cluster of similar cases are identified in the archives or subsequently, the tissue is subjected to molecular studies whichever platform is feasible. When those cases cluster in commonality with respect to genetic rearrangements which translates to clinically divergent prognosis, justifies the cause for those subsets to morph into a new entity. The trigger for identification of new entities is both from the pathologist and the treating physician. When a treating physician perceives the patient is not responding to the time-tested classic therapy of particular tumor or when a pathologist is not able to categorize a tumor into one basket, the communication of information and the transference of perspective amongst each other goes a long way in tailoring the therapy for the particular patient. This asynchrony of the morphology and the patient’s
response to therapy gives an essential thrust for research.

An interesting and well-known example is CIC-dux4 rearranged sarcoma which was previously clumped under Ewing sarcoma because they resembled in morphology and immunophenotype to an extent. Now CIC-dux4 rearranged sarcoma is pathologically and clinically a distinct entity with divergent treatment and prognosis.

The ever-expanding study of molecular aberrations in different tumor subtypes have led to the discovery of many drugs. The so-called ‘druggable tumor specific molecular aberrations’ are validated in clinical trial and then approved by FDA. These druggable molecular aberrations are initially validated across several available testing platforms and the most appropriate type is chosen as a routine diagnostic/prognostic test.

A classic example would be the discovery of NTRK (Neurotropic tyrosine receptor kinase) rearrangements in many tumors. Other than the classical infantile fibrosarcoma, NTRK rearrangements can be seen in a variety of tumors including secretory carcinoma, subset of pediatric gliomas, colorectal carcinoma, melanoma, and cholangiocarcinoma with NTRK rearranged sarcoma joining the list recently. US FDA approved Entrectinib and Larotrectinib, NTRK inhibitors got accelerated drug approval in 2019. Larotrectinib showed age agnostic and histology agnostic responses making it a breakthrough drug.

The Next Generation Pathologist

Pathology is not the same anymore limited to a histologic diagnosis. It is the integration of histologic, molecular, cytogenetic, genomic and epigenetic information into clinically relevant document which conveys the diagnostic, predictive and prognostic information. It is easier said than done. The pathologist must judiciously triage the tissue or specimen which comes to the laboratory for diagnosis anticipating the imminent tests which will be required across different platforms.

Many of the predictive markers can be assessed by immunohistochemistry whereas certain molecular classifications may require the use of cytogenetic and molecular tests ranging from regular PCR (Polymerase Chain Reaction) based assays to next generation sequencing. Appropriate tissue handling, preservation and storage is a critical part of this complex process because all downstream results are dependent on the tissue fidelity.

The future pathologist should be well versed not only with morphology but also molecular pathology which is a subspecialty in itself. A sound knowledge of morphology with an adequate connaissance of molecular pathology sets the apt platform for the genesis of a next generation pathologist which is the need of the hour.

There is a global trend towards sub specializing in pathology akin to surgical oncology where subspecializing is becoming the norm. This molecular era beckons for the realignment of pathology as a specialty where both the educational and the practical aspects of molecular pathology “has” to be intricately woven into the training residency programs with further organ or system based subspecialties. Because gone are the shackles that chained the pathologist to a laboratory, now the role of the pathologist has transcended beyond diagnostics into therapeutics and prognostication aiding the clinician in optimal patient management.

Conclusion

The so-called molecular revolution has ushered in a new era catapulting the pathologist to a different dimension where a banal morphologic diagnosis is not the norm. It calls for the judicious use and application of predictive biomarkers coupled with assessment of tumor mutations using next generation sequencing or other platforms with a tiny piece of tumor tissue at hand. It might not suffice to say that the pathologist transforms this tiny tissue which enters the laboratory into a giant leap of information aiding in optimal patient management and continuous medical knowledge.

References:

When as 1st year resident in general surgery, dealing with lumps and bumps in abdomen, fantabulous appendix, hernia, trauma care, ear repairs, impossible passage of bladder necks at mid nights and early dawns, dressing of burns for hours at length—- ---and then 2nd year residency in GCRI, and hell let loose. Had to face dismal depressive atmosphere and had to work tireless. Oncosurgery was not my choice in male dominated field- but carried on and it became passion.

Those were late 70s where oncology did not see changes in treatment that frequently as today and now there is tremendous progress with newer treatment modalities. Those were the days in oncology which was same world over and now these are the days we have metamorphosed to passionate surgical oncologists, whatever were the challenges always feeling proud of GCRI to have groomed us. That is my journey.

I have witnessed
- most radical ablations to organ preservation
- cobalt, caesium, thorastrone radiotherapy sources to proton beam units
- preventive oncology
- personalised medicines

But as a surgeon, the most captivating changes is in breast oncology.

Breast screening has given mortality benefits as shown by Swedish 2 country trial in 1980 where reduction in mortality is by 25-40%.

The salient features of breast screening are:
1. Optimising organisation of screening which has to be quality oriented and cost effective
2. Setting targets for quality management
3. Optimising interpretation of mammography
4. Setting optimal screening intervals to pick up early interval cases

The advancement in mammography has come up from digital mammography to Digital Breast Tomography (DBT), Contrast Enhanced Spectral Mammography (CESM) and breast MRI. Recommendations come through need for individual patient.

Hence breast cancer detection and treatment has seen vast rapid changes from 1980 onwards. My journey continues.
Haematopoetic Stem Cell Transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to re-establish blood cell production in patients whose bone marrow or immune system is damaged or defective. This helps to augment bone marrow function and depending on the disease being treated, leads to either destruction of malignant tumor cells or to generation of functional cells that can replace the dysfunctional ones, as is the case of immune-deficiency syndromes, hemoglobinopathies, and other diseases. Since it was first used successfully in 1986, HSCT has become one of the most promising treatments for a number of serious illnesses. Over the past half century, this technique has been increasingly used to treat numerous malignant and nonmalignant diseases. The success of HSCT is influenced by a number of factors, including age of patient, general physical conditions, primary diagnosis, status of disease at the time of HSCT and type of donor, etc.

### Stem cells
Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). Cell sources include bone marrow; peripheral blood; umbilical cord blood; or, rarely, fetal liver.

### Conditioning regimen
During the “count down” period, usually five to 10 days before the stem cell infusion, conditioning regimen is administered. The chemotherapeutic agents and/or radiotherapy that are used vary with the underlying disease. The overall goals of the conditioning regimen are to destroy any residual cancer cells in case of autologous transplant. In allogeneic transplant it additionally suppress the immune system so that the patient do not reject the new stem cells and make room in the bone marrow for the donor stem cells to grow.

### Autologous bone marrow transplantation
The bone marrow products are collected from the patient and are reinfused after giving high dose chemotherapy to the patient. The advantages include no graft versus host disease (GVHD). The disadvantage is that the bone marrow products may contain abnormal cells that can cause relapse in the case of malignancy. Hence theoretically, this method cannot be used in all cases of abnormal bone marrow diseases. It is performed for stem cell rescue after high-dose chemotherapy in patients of multiple myeloma, Hodgkin disease, neuroblastoma, plasma cell disorders, etc.

### Syngeneic bone marrow transplantation
The donor and the recipient are identical twins. The advantages include no GVHD and no graft failure. However, only a tiny number of transplant patients will have the ability to have an identical twin for transplantation.

### Allogenic transplantation
The donor is an HLA matched family member, unrelated matched donor or mismatched family donors (haploidentical). It is performed in conditions where replenishment of deficient or dysfunctional cells is required as in Thalassemia, Mucopolysaccharidosis, Aplastic anemia, Gauchers disease or to treat malignant conditions like acute leukemia, non-Hodgkin lymphoma.

### Cord blood transplantation
The source of stem cells is umbilical cord blood. This procedure has not been in much use in India as its storage requirement are not cost effective for developing countries. Moreover, the present storage conditions and availability in India do not provide adequate yield of stem cells for successful transplant. Also improved outcome of haploidentical transplant has outweighed the requirement of cord blood transplantation.
HSCT at GCRI

GCRI began its glorious journey of HSCT under the guidance of Dr Sandeep Shah by performing first autologous transplant in the year 1999 in a patient of multiple myeloma.

The bone marrow transplant centre is a five bedded transplant centre. The institute takes pride in having performed more than 530 transplants over its journey of 23 years in transplant, of which 228 are autologous, 230 allogenic (including 48 haploidentical, and 7 matched unrelated donor transplant), and 17 cord blood transplant until now.

GCRI holds to its credit, performing nations first umbilical stem cell transplantation in a child with thalassemia. Presently umbilical cord blood cell transplantation has fallen out of favour as it exhibits poor outcome in developing countries like India due to poor storage conditions and infrastructure. Additionally, the improving survival outcome of haploidentical autologous HSCT makes it more feasible and cost effective.

Strength / workload

Approximately 50 HSCT transplants a year and hematology OPD twice weekly for complex haematological disorders.

Area of Activity

GCRI excels in conducting HSCT. The centre gets patients from various states of India for autologous and allogeneic transplant for various benign and malignant conditions. Number of haploidentical transplants have increased over recent years for patients who don't have matched sibling donor and are not able to undergo matched unrelated donor transplant.

Bone marrow transplant unit at GCRI has a very high success rate and transplant related mortality (TRM) is comparable to any other institute in the world.
Diagnostic Value of Neutrophil Leukocyte Ratio and Platelet Lymphocyte Ratio to Differentiate Adnexal Masses as Benign or Malignant in the Preoperative Period

Hantodkar Rujuta¹, Patel Bijal¹, Dave Pariseema¹, Parekh Chetana¹, Kar Bijoy²
Resident¹, Professor², Professor & Chief of Unit-II³, Associate professor⁴, Lecturer⁵
Department of Gynaecological Oncology
The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, Gujarat.

Corresponding Author: pariseema.dave@gcriindia.org

Materials and Method
The present retrospective study was conducted at the Gynaecological Oncology Department of the Gujarat Cancer and Research Institute, Ahmedabad. The sample size was 166 cases evaluated from January 2018 to February 2021.
Data collection, compilation and analysis was done by EPI info (version 7.2). The qualitative variables were expressed as percentages. The quantitative variables were categorized and expressed as percentages or terms of mean and standard deviations. The chi-square test was used to interpret the difference between the two proportions. The student t-test was used to evaluate the difference between the two means. The diagnostic performance of the data was measured in terms of sensitivity, specificity, positive predictive value, negative value and diagnostic accuracy. We used receiver operating characteristic (ROC) curves to determine the best cut-off. The analysis was 2-tailed. The significance level was set at 0.05. Based on Youden’s index the best cut-off for NLR was 3.09 [Area under curve=0.615 (0.529 to 0.702), p value=0.012] and for PLR was 203.68 [Area under curve=0.595 (0.509 to 0.682), p value=0.044].

Table 1: Sensitivity, specificity, negative predictive value, positive predictive value and diagnostic accuracy measured of NLR, PLR, CA125 and combination of these parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Sensitivity (lower and upper 95% confidence interval)</th>
<th>Specificity (lower and upper 95% confidence interval)</th>
<th>Positive predictive value (lower and upper 95% confidence interval)</th>
<th>Negative predictive value (lower and upper 95% confidence interval)</th>
<th>Diagnostic accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLR≥3.09</td>
<td>61.33 (50.02 - 71.54)</td>
<td>58.24 (47.98 - 67.84)</td>
<td>54.76 (44.14– 64.96)</td>
<td>53.84 – 74.11</td>
<td>59.64 (52.04 – 66.8)</td>
</tr>
<tr>
<td>PLR≥203.68</td>
<td>60.00 (48.69 - 70.34)</td>
<td>53.85 (43.66 - 63.72)</td>
<td>51.72 (41.37– 61.93)</td>
<td>62.03 (51 – 71.93)</td>
<td>56.63 (49.02 – 63.93)</td>
</tr>
<tr>
<td>CA125 (cut-off 35 U/mL)</td>
<td>67.57 (56.27 - 77.14)</td>
<td>53.85 (43.66 - 63.72)</td>
<td>54.35 (44.2 – 64.15)</td>
<td>67.12 (55.73 – 76.81)</td>
<td>60 (52.38 – 67.17)</td>
</tr>
<tr>
<td>NLR and CA125&lt;35</td>
<td>66.67 (46.71 - 82.03)</td>
<td>61.22 (47.25 - 73.57)</td>
<td>45.71 (30.47– 61.81)</td>
<td>78.95 (63.65 – 88.93)</td>
<td>63.01 (51.55 – 73.18)</td>
</tr>
<tr>
<td>NLR and CA125≥35</td>
<td>58 (44.23 - 70.63)</td>
<td>54.76 (39.95 - 68.78)</td>
<td>60.42 (46.31 – 72.98)</td>
<td>52.27 (37.94 – 66.25)</td>
<td>56.22 (46.33 – 66.19)</td>
</tr>
<tr>
<td>PLR and CA125&lt;35</td>
<td>50 (31.43 - 68.57)</td>
<td>53.06 (39.38 – 66.30)</td>
<td>34.29 (20.83– 50.85)</td>
<td>68.42 (52.54 – 80.92)</td>
<td>52.05 (40.78 – 63.12)</td>
</tr>
<tr>
<td>PLR and CA125≥35</td>
<td>66.30 (50.14 - 75.86)</td>
<td>54.76 (39.95 – 68.78)</td>
<td>62.75 (49.02 – 74.68)</td>
<td>56.10 (41.04 – 70.11)</td>
<td>59.78 (49.57 – 69.22)</td>
</tr>
</tbody>
</table>

All the women who had preoperative ultrasonography showing adnexal masses, CA125 and a CBC within one month of surgery and whose final histopathology showed ovarian pathology were included in the study. Those cases who were already operated outside or had received preoperative chemotherapy were excluded from the study. Fungal and tubercular infections causing adnexal masses were also excluded to remove bias as they also cause an increase in leucocytes and would distort the outcome of the study. On retrospective examination of the histopathological results, out of 166 cases studied, 91 were benign and 75 were either borderline or malignant. All borderline and malignant cases were considered together as a single category.

The CBC, CA125 reports and the final histopathological reports were reviewed retrospectively. The data of neutrophils, lymphocytes, absolute neutrophil count, absolute lymphocyte count and thrombocyte count were collected from CBC reports. NLR and PLR were calculated from these values.

Data collection, compilation and analysis was done by EPI info (version 7.2). The qualitative variables were expressed as percentages. The quantitative variables were categorized and expressed as percentages or terms of mean and standard deviations. The chi-square test was used to interpret the difference between the two proportions. The student t-test was used to evaluate the difference between the two means. The diagnostic performance of the data was measured in terms of sensitivity, specificity, positive predictive value, negative value and diagnostic accuracy. We used receiver operating characteristic (ROC) curves to determine the best cut-off. The analysis was 2-tailed. The significance level was set at 0.05. Based on Youden’s index the best cut-off for NLR was 3.09 [Area under curve=0.615 (0.529 to 0.702), p value=0.012] and for PLR was 203.68 [Area under curve=0.595 (0.509 to 0.682), p value=0.044](Figure 1 and Figure 2). The cut-off for CA125 is 35 U/mL.
Result

A total of 166 women with ultrasound showing adnexal masses were enrolled. The patient distribution as per their final histopathological reports showed that 91 cases (54.82%) were benign whereas 75 cases (45.18%) were either borderline or malignant. All borderline and malignant cases were considered together as a single category.

The specificity of CA125 (67.57%) is better than NLR (61.33%) or PLR (60%) whereas the sensitivity was better when NLR was considered with CA125<35 (61.22%). This indicates that CA125 is a better marker than NLR or PLR alone or even if considered together with CA125, to distinguish malignant from benign ovarian masses preoperatively. But if CA125 is less than 35 IU/ml and NLR < 3.09, then the chances of the ovarian mass being benign are more. The best positive predictive value is indicated by PLR and CA125≥35 together (62.75%) whereas the best negative predictive value is seen with NLR and CA125<35 (78.95%). Therefore, if CA125 is more than 35 and PLR ≥ 203.68, the ovarian mass is likely to be malignant. If NLR<3.09 and CA125<35, the ovarian mass is more likely to be benign. As per the statistics, the diagnostic accuracy of NLR and CA125<35 is better (63.01%) than the other parameters (Table-1).

Discussion

The carcinogenesis of different types of tumors, including ovarian cancer (OC), has been associated with chronic inflammation. There are multiple mechanisms involving inhibition of apoptosis, angiogenesis, non-repair or deliberate DNA damage, and overexpression of cytokines and inflammatory mediators which advance this process. In addition, SIR mediators weaken the immune system. This causes an increase in the concentrations of leukocytes, neutrophils, platelets, C-reactive protein (CRP) and fibrinogen, and decreased levels of albumin and lymphocytes. The majority of adnexal masses are benign and only ~20% are malignant. Hence the identification of novel markers in the preoperative period to determine the nature of the suspected adnexal masses has become essential.

In the present study, we evaluated and compared CBC parameters alone and in combination with the CA125 levels and their diagnostic accuracy in 166 women with various types of ovarian tumors. We showed that the NLR, the PLR or their association with CA125 could not present a superior performance in the prediction of malignancy in the preoperative setting which was also proved by Yoshida et al, but opposed to Khatib et al and Cramer et al, whose studies prove the contrary to be true. Although in our study NLR and CA125<35 had the best negative predictive value, specificity and diagnostic accuracy out of all the parameters considered, these values are only fairly significant. This parameter may be useful to distinguish benign from malignant ovarian masses, but its clinical significance needs to be studied further.

NLR and PLR in our study show better sensitivity than specificity as compared to the study by Yoshida et al whose results had better specificity than sensitivity. According to present study, NLR and PLR alone are only fairly significant to indicate preoperatively whether the adnexal mass is malignant.

Conclusion

Given the discrepancies in the results of various studies and the non-uniformity in the cut-off values for NLR and PLR, more studies need to be conducted to determine the cut-offs and also their clinical significance. Our study showed better statistical significance of NLR in combination with CA125 rather than with NLR alone. Hence, the significance of NLR and PLR with other sociodemographic factors as well as other biomarkers needs to be studied to further evaluate their significance to distinguish adnexal masses preoperatively to help make suitable therapeutic decisions.

References:

Human beings these days are more engrossed in negativity and hopelessness. The spirit of liveliness for life has become a rare quality. As a consequence, we often encounter depressed souls lamenting over life and its hustles, rather than lively people who celebrate and enjoy every moment of life.

I fondly remember one of my young patient who made me think of being courageous in life and continue working without worrying about results. A three-year-old boy was diagnosed to have neuroblastoma, a life threatening cancer. On investigations he was found to have very aggressive tumour and required to undergo intensive treatment with chemotherapy and bone marrow transplant. He received intensive chemotherapy without any tantrums and was admitted for the bone marrow transplant. He was aware that during the course of transplant he will be confined to a room for almost two weeks and will not be allowed to go out till he recovers completely. The little champ entered the room without any fuss and we did not encounter any resistance while preparing him for the daily treatment doses. As a habit while getting ready for my daily morning rounds, I used to watch him from outside the room through a glass window. He would diligently blow a balloon given to him for lung exercises. While on rounds, he engaged us all in energetic chit-chats about his friends, family, favourite chores and would give me an energetic hi-five to bid bye. To our plight during the course of BMT, he developed severe oral ulcers, causing him throat pain along with fever. It became difficult for him to swallow meals or water without severe pain. While prepping up for my morning rounds, I assumed he must be sleeping or crying because of pain and must be asking to go home. But to my surprise when I looked at him from the glass window, he was blowing the balloon as usual. Although he couldn't speak because of throat pain, he happily allowed me to examine him completely and gave me the usual warm hi-five. He did not ask about his discharge even once in his fifteen days stay inside the room. This incident surprised me as I often encounter adult patients becoming cranky when they develop similar complications, they stop doing their daily activities and start whining often asking to go out to meet people.

In this fast paced world seeking instant gratification most of us have forgotten the art of living. People find it difficult to live in the present moment, while they keep contemplating for the future. In this conundrum they miss out living life for what it offers and taking up challenges as part of life. Most of us are busy finding faults in the system, blaming fate, cursing others for incompetency, and become unhappy seeing other people happy. We try to find excuses to run away from the daily discipline and would find reasons to not work hard and fret about not getting the desired results. This child did not refuse or find excuses to run away from treatment. He was doing his daily routine happily and did not bother about what was going to happen next. We adults forget to adopt the basic life tools of discipline, patience and perseverance, which makes us anxious and sad.

I remember another young soul, a 15 years old girl, who was diagnosed with a bone tumor called Ewing’s sarcoma. She underwent surgery to remove the tumor and received chemotherapy for almost a year. Unfortunately, her tumor progressed at the end of treatment and spread to lungs and other bones. Her condition worsened rapidly and she developed breathlessness requiring oxygen support, and was not able to speak or eat because of the distress. Her worsening health condition saddened her parents. They started avoiding conversation about the disease condition with their daughter and pretended to be happy when with her, as they felt this would further demotivate her from receiving the palliative care. The girl however had understood that the tumor has spread everywhere and she was not going to make it. What caught my attention was her understanding for her parents’ mental state and agony. I was surprised to see her acceptance for her unfortunate fate. On my visit to her, she would request me to comfort her parents to not worry and give them hope by telling them that she will be fine after one dose of medication. She would often request me to give her some medications which could...
reduce her breathing difficulty so that she can talk with her parents and eat well and not make them anxious. While doing so she did not become depressed thinking that she is not going to get cured. She understood the limitations of treatment strategies and never demanded that she should be cured by any means. Never did she expressed the desire to run away from the hospital where so far she received only pricks and pain without any benefit. She did not exhibit any tantrums, which we expect from older children or adolescents.

This girl was brave and happy even at the end of her life. She lived the time that she had in hand with her. We many times burden ourselves with lot of expectations from life. In the run of life, we forget to live and keep chasing the unending trail of targets set by us. We ascribe life with terms and conditions while missing out on cherishing that it has to offer. People undermine the importance of spending quality time with family and people around us, and seldom connect with nature. While coping with the self-created overwhelming stress for life, we often start acting on spinal level and operating like robots. These are the root reasons that make people unhappy, predisposing them to anxiety and depression. There is a need to slow our pace while running from posts to pillar chasing happiness and targets which are actually pseudo destinations set by us. We should remember to savor small moments in this journey of life while cherishing the present.

We need to learn to be alive even at our deathbed like this girl instead of living life like a lifeless person.

Living one day at a time,
Enjoying one moment at a time,
Accepting hardship as a pathway to peace,
Taking, as He did,
This sinful world as it is,
Not as I would have it,
Trusting that He will make all things right,
If I surrender to His will,
That I may be reasonably happy in this life,
And supremely happy with Him forever in the next.

Amen
Squamous Cell Carcinoma of External Auditory Canal Metastasis to CSF: A Diagnostic Conundrum

BR Nagarjun\(^1\), Patel Trupti\(^1\), Shah Majal\(^1\), Dhandapani Kartik\(^1\)
Resident\(^1\), Associate Professor\(^2\), Assistant Professor\(^3\)
Department of Oncopathology,
The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, Gujarat
Corresponding Author: trupti.patel@gcriindia.org
\(^1\)https://orcid.org/0000-0002-5158-9236
\(^2\)https://orcid.org/0000-0002-5887-2042

Introduction

CSF cytology is a routinely practised test due to its simplicity, diagnostic ability and prognostic significance. In oncology practise, CSF examination is commonly performed to rule out Central Nervous System (CNS) infection in view of chronic immunosuppression, in dwelling vascular catheter, head and neck surgeries and CNS metastasis which affects the therapeutic management and clinical outcome.\(^1\)\(^2\) Presence of tumor cells in leptomeninges or CSF away from primary tumor is defined as leptomeningeal metastasis (LM).\(^3\)\(^4\)

Metastatic carcinomas from lung, breast, gastrointestinal tract are commonly reported.\(^5\) SCC involving CSF is extremely rare with few case reports mentioning different sites of head and neck region as primaries.\(^6\) Incidence of SCC of EAC is rare with a reported incidence of between 1 to 6 cases per million population per year and metastasis to CSF is unreported.\(^5\)

Case Detail

A 40-year male patient presented to emergency department (ED) with complains of left sided facial weakness and hoarseness of voice. MRI brain revealed peripherally enhancing hypo intense lesion with absence of perilesional edema measuring 15x8mm in left temporal lobe suggesting possibility of brain abscess. (Figure 1) Patient was diagnosed case of SCC of left EAC a year back and on chemotherapy with regular follow up showing signs of improvement. Tumor did not show any direct extension into the brain parenchyma (Figure 1).

Presently patient had no complaints of fever and on examination signs of meningitis were not elicited. Microbial etiology was suspected as the patient had already completed 5 cycles of carboplatin and paclitaxel, lumbar puncture was performed and CSF tapped was subjected for biochemical, microbiological and cytological examination.

CSF Examination

CSF sample collected by lumbar puncture was around 6ml and clear in appearance. Biochemical examination revealed hypoglycorrhachia (15.34 mg/dl), raised protein (176.11 mg/dl), chloride of 121.6 mmol/dl. Wet mount preparation suggested hyaline round structures similar to size of RBCs and considered a possibility of cryptococcal infection. However, CSF culture was sterile after 14 days of incubation.

CSF Cytology

Cytoprep and papanicolaou stained smears
examined were highly cellular with malignant tumor cells arranged in clusters and scattered singly. Tumor cells had variable nuclear size, regular nuclear contour, round to oval nuclei, fine chromatin and mild to moderate amount of cytoplasm. (Figure 2A) Tumor giant cells and few bizarre cells were noted amidst scattered lymphocytes and macrophages. Structures resembling microorganisms was not identified. Cell
block prepared by fixed sediment method and stained by hematoxylin and eosin revealed pleomorphic cells having fine to vesicular nuclei and moderate amount of cytoplasm with plenty of artifactual cytoplasmic vacuolations. (Figure 2B)

Discussion
Carcinomas metastatizing to CSF is a complication in the natural course of disease and is seen in 5-8% of solid tumors. LM spread from SCC is exceedingly rare with case reports from various sites of head and neck (lip, oropharynx, larynx, nasopharynx), lung, genitourinary and skin. Occurrence of SCC in EAC is quite uncommon and metastasis to CSF is unreported based on PubMed search.

In this case, clinical and radiologic findings had a very minimal suspicion of metastasis to CSF. Cyto-morphologically also the tumor cells in CSF failed to show any squamous features such as thick, dense cytoplasm with well-defined cell borders or keratin pearls. The common primaries such as of adenocarcinoma from lung or GIT was considered but glandular morphology of tumor cells and supporting radiological findings were absent. No evidence of moulding was seen to suspect small cell carcinoma lung. Possibility of melanoma was ruled out due to absence of large cells with macronucleoli or melanin pigment.

Since the tumor morphology at the primary site was predominantly basaloid (Figure 2E), the metastatic spread was confirmed by the same immunohistochemical panel applied on the biopsy. AE1/AE3 and p63 confirmed the squamous nature of the tumor and reinforced the fact that primary was from EAC. (Figure 2C-D, 2F-G). Generally, identification of malignant squamous cells in CSF is limited and require repeated tapping in addition it is uncommon to encounter the characteristic cytology which adds to the diagnostic difficulty. Despite immunocytochemistry aids in diagnostic accuracy, is limited if the cellularity is low.

Several mechanisms of CSF involvement have been postulated with perineural mode commonly described in SCC metastasis. The mode of CSF involvement in our case has occurred as direct extension through temporal bone.
Primary Pleomorphic Liposarcoma of Bone: A Rare Tumor in Unusual Location with Review of Literature

Vanik Sangeeta A, Gami Amisha, Kaur Kanwalpreet, Trivedi Priti
Assistant Professor, Professor
Department of Oncopathology,
The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, Gujarat
Corresponding Author: priti.trivedi@gcriindia.org
https://orcid.org/0000-0002-6821-6129

Summary
Primary liposarcoma of bone is an extremely rare tumor and accounts for only 0.03% of all primary bone tumors. Herein we report two rare cases of primary pleomorphic liposarcoma of long bone. Both cases presented with localised swelling and pain. Imaging study revealed that origin of tumor was primarily of bone. J needle biopsy in both cases showed highly pleomorphic cells with no malignant osteoid. Diagnosis of high-grade sarcoma was given. Histomorphology of post-chemotherapy resected specimens showed many pleomorphic lipoblasts with large areas of necrosis and no malignant osteoid. After ruling out the various differentials, final diagnosis of primary pleomorphic liposarcoma of bone were given in both cases. Hence, biopsy material alone is very challenging for the diagnosis. Careful histopathological examination with keeping in mind of a rare diagnosis along with a clinicoradiological correlation as well as immunohistochemistry play a useful role in confirmation of the diagnosis.

Keywords: Malignant bone tumor, Pleomorphic liposarcoma, Liposarcoma of bone, Rare primary bone tumor

Introduction
Primary liposarcoma of bone is an extremely rare tumor, with prevalence of only 0.03% among all bone tumors. In 1955, Dawson reported the first convincing case of primary liposarcoma of bone. Subsequently over the years other authors also reported this rare entity. But in 1982, Addison and Payne reviewed all and found only 6 convincing cases. Among all malignant adipocytic tumors, Pleomorphic Liposarcoma (PLS) was least common. We report two cases of primary PLS of bone with the aim to enrich the existing literature and a focus on potential pitfalls in diagnosis.

Case Details
Twenty-six and 16-year-old young males presented with pain and swelling in their left knee joint for 2 past months. Magnetic resonance imaging (MRI) revealed ill-defined tumor involving epi-meta-diaphysis of distal femur and proximal tibia, respectively. Both the cases showed altered marrow signal intensity which appeared hypointense on T1W and heterogeneously hyperintense on STIR with associated periosteal reaction, periosteal thickening and soft tissue component. Possibility of primary malignant bone tumor? Osteosarcoma was suggested in both the cases.

J needle biopsy of both the cases showed clusters of atypical cells having highly pleomorphic, hyperchromatic nuclei, irregular nuclear membrane and vacuolated cytoplasm. Malignant osteoid were not identified in both the cases (Figure 1a). Correlation of histopathology with clinicoradiological findings, diagnosis of high-grade sarcoma with possibilities of osteosarcoma with clear cell component, pleomorphic liposarcoma and metastatic carcinoma were given.

Both the cases received chemotherapy followed by surgery. Gross feature of case 1 showed, a 17x17x6 cm tumor involving the epi-meta-diaphysis of left distal femur. Cut surface was mainly necrotic (≥ 90%) and bony area was solid, greyish white to tan. (Figure 1b). Case 2 showed, a 17x8x6 cm tumor involving epi-metaphysis of left proximal tibia. Cut section of tumor was solid, greyish yellow to white, soft to firm, also areas of necrosis were evident. Both showed soft tissue extension and case 2 also showed overlying skin ulceration. Microscopic examination of both the cases showed many uni- and multi-vacuolated pleomorphic lipoblasts with extreme pleomorphism, brisk mitotic activity and areas of necrosis. Malignant osteoid were not identified. (Figure 1c, 2a, b).

Differential diagnosis include metastatic pleomorphic liposarcoma, primary pleomorphic liposarcoma, high grade osteosarcoma, dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma. Both patients were screened by positron emission tomography and computed tomography PET-CT scan which suggested primary bone tumor with no distant metastasis at time of diagnosis. Absence of malignant osteoid and no well differentiated liposarcomatous area ruled out osteosarcoma and dedifferentiated liposarcoma respectively. Presence of typical pleomorphic lipoblasts ruled out the undifferentiated pleomorphic sarcoma.

IHC was done to rule out the various differentials. Tumour cells were immunoreactive for vimentin, focally for S100 protein and negative for SATB2. (Figure 1d, e, f, Figure 2c, d).
Figure 1: Case 1/ (a) H and E staining from J needle biopsy showed many atypical cells with hyperchromatic nuclei and vacuolated cytoplasm 20x (b) Gross photograph of post chemotherapy specimen (c) Many pleomorphic lipoblasts in resection specimen 40x (d to f) Immunohistochemical stains 20x (d) vimentin(cytoplasmic) positive (e) S100 protein (nuclear and cytoplasmic) focal positive (f) Negative SATB2.

Figure 2: Case 2(a, b) Histomorphology of resected specimen shows many pleomorphic lipoblasts 40x (c,d) Immunohistochemical stain (c) vimentin (cytoplasmic) positive (d) S100 protein (nuclear and cytoplasm) focal positive.
Table 1: Previously reported cases of pleomorphic liposarcoma of bone

<table>
<thead>
<tr>
<th>Study</th>
<th>Age/sex</th>
<th>Site</th>
<th>Metastasis</th>
<th>Treatment received</th>
<th>Follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Torok et al&quot;</td>
<td>34/M</td>
<td>Femur</td>
<td>Lung</td>
<td>Wide resection, radiation, chemotherapy</td>
<td>Died, 16 months</td>
</tr>
<tr>
<td>Hamlat et al&quot;</td>
<td>45/F</td>
<td>Thoracic spine</td>
<td>Lung and rib</td>
<td>Laminctomy T7-T8 and radiotherapy</td>
<td>Alive, 19 months</td>
</tr>
<tr>
<td>Torigoe et al&quot;</td>
<td>38/F</td>
<td>Humerus</td>
<td>Liver</td>
<td>Wide resection, Initial high-dose ifosfamide followed by cisplatin and doxorubicin</td>
<td>Died, 8 months</td>
</tr>
<tr>
<td>Lmejjati et al&quot;</td>
<td>35/M</td>
<td>Lumber spine</td>
<td>Locally invasive</td>
<td>Emergency decompression at L4/L5 and radiotherapy</td>
<td>Died, 3 months</td>
</tr>
<tr>
<td>Rasalkar&quot;</td>
<td>13/M</td>
<td>Femur</td>
<td>Lung</td>
<td>Neoadjuvant chemotherapy (methotrexate, cisplatin), Surgery, Adjuvant chemotherapy (ifosfamide/etoposide and Adriamycin/cisplatin)</td>
<td>Alive, 13 months</td>
</tr>
<tr>
<td>Tiemeier GL et al&quot;</td>
<td>18/M</td>
<td>Tibia</td>
<td>Femur and lung</td>
<td>Chemotherapy (methotrexate, doxorubicin and cisplatin), wide resection</td>
<td>Alive, 12 months</td>
</tr>
<tr>
<td>Fajolu O et al&quot;</td>
<td>19/M</td>
<td>Femur</td>
<td>Lung, liver,vertebra, scapula</td>
<td>Chemotherapy (etoposide,ifosfamide) and wide resection</td>
<td>Died, 8 months</td>
</tr>
<tr>
<td>Our study</td>
<td>16/M</td>
<td>Tibia</td>
<td>Contralateral Femur</td>
<td>Chemotherapy and wide resection</td>
<td>Lost follow up after 7 months</td>
</tr>
<tr>
<td></td>
<td>26/M</td>
<td>Femur</td>
<td>-</td>
<td>Chemotherapy (Doxorubicin, cisplatin), wide resection</td>
<td>Died, 6 months</td>
</tr>
</tbody>
</table>

After excluding all differentials final diagnosis of primary pleomorphic liposarcoma of bone were given in both the cases. Case 2 also showed metastasis to the contralateral side of distal femur after 2 months of initial diagnosis.

Both cases were followed up. Case 1 died after 6 months of initial symptoms, while we lost follow up of case 2 after 7 months of initial symptoms.

Discussion

Malignant adipocytic tumor accounts for 10-35% of all soft-tissue sarcomas, and PLS is the least common subtype, with prevalence of only 5-15% of all liposarcomatous lesions. Liposarcoma arising from the bone is a rare entity and very few confirmed cases of primary PLS of bone have been reported in literature. Total of 1008 primary malignant bone tumors were reported between 2018 to 2020 in our hospital. Most common primary malignant bone tumor was osteosarcoma (57.83%) followed by Ewing sarcoma (26.58%) and chondrosarcoma (15.37%), and only two cases of primary liposarcoma of bone were reported. Till date only 7 cases of primary PLS of bone have been reported in literature (Table 1). Diagnosis of primary liposarcoma of bone can be considered only if it arises from the bone and have characteristic gross and histological features.

Primary PLS of bone affect a wide age range from 15-53 years and equally affects both genders. Long bones of lower extremities and upper extremity most frequently affected while rarely it can affect scapula, maxilla and mandible.

Radiology of primary liposarcoma of bone shows non-specific features such as large osteolytic lesion with cortical destruction. PLS contain less adipocytic component as compared to other subtypes and this makes imaging diagnosis difficult. MRI study shows intermediate signal intensity with T1 weighting and intermediate to high signal intensity with T2W. These findings were concordant with our cases.

Histomorphology of PLS includes a lipogenic area with variable number of pleomorphic lipoblasts and non-lipogenic area with high grade sarcoma features. Both our cases had similar histomorphology with lipogenic areas showing many pleomorphic lipoblasts and non-lipogenic areas having high grade sarcomatous features.

Immunohistochemistry and molecular analysis have very limited diagnostic role. Murine Double Minute 2 (MDM2) amplification is negative in PLS while osteosarcoma, low grade and parosteal and those that dedifferentiate into high grade osteosarcoma show positive staining. Gebhard et al, observed that S-100 protein immunoreactivity was seen in up to 48% of lipogenic areas which were concordant with our cases.

Primary osseous liposarcoma is an aggressive malignancy with mean survival rate of two years only. Wide surgical resection is the mainstay of
treatment of primary osseous liposarcoma, with radiation therapy used for palliation or following excision to prevent local recurrence. Both our cases received chemotherapy prior to surgery. One patient succumbed to death post operatively while another showed osseous metastasis in contralateral long bone. However, we lost follow up of the patient after this.

Conclusion
Primary pleomorphic liposarcoma of bone is an extremely rare tumor. Diagnosis alone on biopsy material is very challenging. Due to rarity of tumor, despite the presence of lipoblasts, one may still miss the diagnosis if not aware of the entity.

Conflict of interest
No conflict of interest.

Acknowledgements
None

References:
Recurrence Developing 21 Years After Treatment of Breast Cancer

Vagashiya Vidhī, Mehta Maitrik, Parikh Ankita, Shah Sonal, Suryanarayan U
Resident, Professor, Associate professor
Department of Radiation Oncology,
The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, Gujarat
Corresponding Author: maitrik.mehta@gcriindia.org
https://orcid.org/0000-0001-6503-9182

Summary

Background: Breast cancer is a very common cancer among females. In which most recurrences (around 75%) occur within the initial 5 years after diagnosis, especially within 3 years. Recurrence after 20 years is very less reported in the last few decades.

Case Information: We present the case of a 67-year-old woman who presented with pleural based nodules suggestive of lung metastasis followed by brain metastasis. After reviewing history, we came to know that the patient was a previously treated case of breast carcinoma treated 22 years back with mastectomy.

Conclusion: We report late recurrence of breast cancer occurring 21 years after mastectomy suggesting that possibility of recurrence in carcinoma breast with a 21-years latency period although rare should be taken into consideration when making decisions regarding patients who may need long term follow up.

Keywords: late recurrence, breast cancer

Introduction

Understanding the risk of recurrence more than 10 years after primary diagnosis helps distinguish patients who may be candidates for long-term follow-up. After diagnosis of 1847 patients who underwent breast-conserving surgery between 1989 and 1999 in a Danish study showed a cumulative incidence of 15% for local recurrence and 21% for distant metastases after 20 years post diagnosis.

Case Report

A 67-year-old postmenopausal female presented with chief complaints of right limb weakness, headache with constipation for 6 days in August 2021. There was no associated complaint of fever, seizures, or loss of consciousness. On taking detailed history, she was a known case of carcinoma of the left breast. Estrogen and progesterone receptor negative and HER2/neu positive diagnosed and treated 22 years before. She had undergone modified radical mastectomy + 5 cycle CMF (5-FU, methotrexate and endoxan) chemotherapy treatment for the same. Patient did not receive any adjuvant radiotherapy. The patient was started on tablet tamoxifen and continued the same till 5 years. Patient was then lost to follow up for two years and presented back to our institute in August 2008 after which the patient was kept under observation.

Patient then presented with a complaint of right sided chest pain in August 2020. CT scan of September 2020 showed recurrent lesion involving left anterior chest wall, precarinal node, upper para aortic node with bilateral lung and bone metastases.

Immunohistochemistry (IHC) of CT guided lung biopsy was suggestive of metastatic ductal carcinoma (GATA -3 +ve) with ER +ve, PR -ve and Her2/neu negative.

CT guided lung biopsy showed poorly differentiated carcinoma with IHC showing metastatic ductal carcinoma. Patient received 3 cycles of paclitaxel. Patient was kept on letrozole for one year. Patient presented to us with right upper limb weakness. On examination, the patient was unconscious and disoriented with power 1 out of 5 in all limbs except 4 out of 5 in the left upper limb with decreased sensation and constipation for 6 days.

Routine blood investigations were normal. NCCT of the brain was suggestive of 24x13 mm left occipital metastasis. CT scan showed residual lesion and D9 vertebrae metastasis with lesion involving left high parietal region, left occipital region.

Patient was referred to the department of radiation oncology for palliative whole brain radiation therapy (WBRT). The patient was planned for palliative WBRT of a dose schedule of 3000 cGy in 10 fractions at 3 Gy in each fraction daily to be completed in 2 weeks through two parallel opposed fields. However, the patient took discharge against medical advice without starting WBRT.

Discussion

Breast cancer is seen as more of a chronic disease where survival curves start to parallel that of the general population after 10 to 25 years. In breast cancer we cannot define a period after which a patient can be considered cured as it is seen with curable acute malignancies. In breast carcinoma, late relapses are observed frequently. Statistical cure is considered if the patient's survival curve parallels that of the general population. The high-risk breast cancer group achieve statistical cure earlier than low-risk group...
(respectively 10–15 vs 20–25 years after diagnosis). As seen from the survival curves, it's starting to match the survival curve for the general population earlier than early stage breast cancer.

According to a study by Rikke Nongaard Pedersen et al, recurrences have been reported in literature as occurring even up to 32 years after diagnosis of the primary. Women with large tumor size, higher lymph node burden and ER-Positive tumors show higher late recurrence risk.

Even though the statistics of these patients of carcinoma breast shows that long term disease free survival can be achieved with adequate treatment in early stages, it remains a question that - after how many years of disease free survival we can guarantee that the patient will have 0% chances of relapse.

**References:**


<table>
<thead>
<tr>
<th>Sr No.</th>
<th>Date</th>
<th>Speaker / Department</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13.01.2022</td>
<td>Patel Vivek Medical Oncology</td>
<td>Pre-operative Neoadjuvant Chemotherapy Cycles and Survival in Newly Diagnosed Ovarian Cancer: What is the Optimal Number? A Memorial Sloan Kettering Cancer Centre Team Ovary Study</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tarun B Surgical Oncology</td>
<td>Short-course Radiotherapy Followed by Chemotherapy Before Total Mesorectal Excision (TME) Versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-label, Phase 3 Trial</td>
</tr>
<tr>
<td>2</td>
<td>27.01.2022</td>
<td>Verma Naveen Surgical Oncology</td>
<td>Postoperative Concurrent Radiotherapy and Chemotherapy for High Risk SCC in Head and Neck Malignancy (RTOG9501)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Baranda Sheetal Anaesthesiology</td>
<td>Anatomic Accuracy of Airway Training Manikins Compared with Humans</td>
</tr>
<tr>
<td>3</td>
<td>10.02.2022</td>
<td>Shukla Shivang Surgical Oncology</td>
<td>Minimally Invasive Lung Surgeries (Uniportal VATS) – GCRI Experience</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rachh Swati Nuclear Medicine</td>
<td>Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal and Colorectal Cancers</td>
</tr>
<tr>
<td>4</td>
<td>22.02.2022</td>
<td>Kapoor Shilpa Oncopathology</td>
<td>CIMPACT – Now Updates and their Significance to Current Neurooncology Practice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abhilash V Gynaecological Oncology</td>
<td>The Systemic Therapy of Recurrent Ovarian Cancer Revisited from Annals of Oncology</td>
</tr>
<tr>
<td>5</td>
<td>10.03.2022</td>
<td>Patel Nupur Immunohematology</td>
<td>Exosomal miRNA Profiles of Triple Negative Breast in Neoadjuvant Treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chandra Minu Medical Oncology</td>
<td>Aromatase Inhibitors Versus Tamoxifen in Premenopausal Women with Oestrogen Receptor-positive Early-stage Breast Cancer Treated with Ovarian Suppression: A Patient-level Meta-analysis of 7030 Women from Four Randomised Trials</td>
</tr>
<tr>
<td>6</td>
<td>24.03.2022</td>
<td>Shah Veer Surgical Oncology</td>
<td>Perioperative Chemotherapy with Fluouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluouracil or Capecetabine Plus Cisplatin and Epirubicin for Locally Advanced, Rectable Gastric or Gastro-oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shah Anand Community Oncology</td>
<td>Determinants of Compliance for Breast and Cervical Cancers Screening among Female Police Personnel of Mumbai, India – A Cross Sectional Study</td>
</tr>
<tr>
<td>7</td>
<td>25.04.2022</td>
<td>Yadav Varun Palliative Medicine</td>
<td>End-Of-Life Care Policy: An Integrated Care Plan for The Dying</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gajjar Kinjal Molecular Diagnostics &amp; Research Lab I</td>
<td>Association of Expression of Inflammatory Response Genes and DNA Repair Genes in Colorectal Cancer</td>
</tr>
<tr>
<td>8</td>
<td>12.05.2022</td>
<td>Prasad Reech Radiodiagnosis</td>
<td>MR Enterography and its Role in Evaluation of Small Bowel Pathologies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shah Vrashesh Neuro Oncology</td>
<td>Endoscopic Pituitary Surgery: Study of 250 Cases Per Operative Variant, Approach, and Local Changes by Pathology</td>
</tr>
<tr>
<td>9</td>
<td>26.05.2022</td>
<td>Chakravarty Sutanuka Radiation Oncology</td>
<td>A Rare Vulval Benign Tumor (Buschke Lowenstein Tumor) Treated with Radical Radiotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bhalala Neha Molecular Diagnostics &amp; Research Lab II</td>
<td>Droplet Digital PCR Assay for Detecting TERT Promoter Mutations in Patients with Glioma</td>
</tr>
</tbody>
</table>
About the Journal and Instructions to Authors

About the Journal

Gujarat Cancer Society Research Journal is a biannually (April and October) peer-reviewed journal published by the Gujarat Cancer Society (formerly published as GCS Research Bulletin). The journal's full text is available online at http://www.cancerindia.org

Scope of the Journal

The Journal intents to cover basic, clinical, clinico-basic research and medical education carried out by the staff of the Gujarat Cancer Society and Gujarat Cancer and Research Institute related to human well being including ethical and social issues in the field of Oncology. The Journal gives preferences to original scientific papers, case reports, anecdotal reports and minireviews. It may comprise invited review articles, publish oration speeches and work presented in the clinical meetings and the journal clubs. Hence it will continue to serve as an academic-research bridge between the basic sciences and the applied sciences, viz. various disciplines of medicine within and outside GCS-GCRI.

Authorship Criteria

Authorship credit should be based only on contributions any of the following components mentioned below:

- Concept and design of study or acquisition of data or analysis and interpretation of data;
- Drafting the article or revising it critically for important intellectual content; and
- Final approval of the version to be published.

Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content of the manuscript.

The order of contributors should be based on the extent of contribution towards the study and writing the manuscript.

It is highly recommended that all authors provide their “Open Researcher and Contributor ID” (ORCID) when submitting a paper. Visit https://orcid.org/ for further information and to register.

Review Process

The submitted manuscripts not meeting with the Instructions to Authors would be returned to the authors for technical correction, before they undergo editorial/peer-review process. The editors will review all submitted manuscripts initially for suitability for formal review. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message will be rejected before proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to the Gujarat Cancer Society Research Journal readers are also liable to be rejected at this stage itself. Manuscripts that are found suitable for publication in Gujarat Cancer Society Research Journal are sent to expert reviewer/s.

The journal follows a double-blind review process, therein the reviewer/s and authors are unaware of each other's identity. Every manuscript is also assigned to a member of the editorial team, who based on the comments from the reviewer/s takes a final decision on the manuscript. The comments and suggestions (acceptance/rejection/amendments in manuscript) received from reviewer/s are conveyed to the corresponding author. If requisite, the author is requested to provide a point by point response to reviewers' comments in a separate sheet and submit a revised version of the manuscript with the changes duly highlighted in different color.

This process is repeated till reviewers and editors are satisfied with the manuscript. Manuscripts accepted for publication are copy edited for grammar, punctuation, print style, and format. Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs within two days.

Copyright

Contents of the Gujarat Cancer Society Research Journal are covered by copyright. Gujarat Cancer Society Research Journal does not accept any responsibility for the statements made by the authors. The Editorial Board has the right to introduce such changes in the articles as may be considered necessary for effectiveness of communication.

Plagiarism

Plagiarism is considered by the Gujarat Cancer Society Research Journal as serious professional/scientific/publication misconduct. Each manuscript submitted to the Gujarat Cancer Society Research Journal shall be subjected to thorough plagiarism check with professional plagiarism detection iThenticate software as well as scrutiny by the editorial team before processing the manuscript. Authors are themselves responsible to ensure that a submitted manuscript is free from plagiarism. Authors and reviewers are advised to be careful to maintain high ethical standards as per existing international norms.
Ethics

Do not use names and initials of patient or hospitals numbers, especially in illustrative material. When informed consent for the same has been taken from the patient, it should be mentioned in the manuscript. Any report of experimental investigation on human subjects must contain evidence of informed consents by the subjects and of approval by the institutional ethics committee.

Units and abbreviations

Avoid abbreviations in the title and abstract. All unusual abbreviations should be fully explained at their first occurrence in the text. All measurements must be in metric units, preferably with corresponding SI units in parentheses. No periods, no plural form (eg. '10 cm' not '10 cms').

Name of Drugs

Use only generic names of drugs. In case trade names (Proprietary drugs) are used, the manufacture should be identified clearly.

Submission of Manuscripts

All manuscripts must be submitted on gesjournal2012@geriindia.org along with scanned IRC approval letter duly addressed to the editors. One hard copy of the same along with covering letter through the Head of the department should be submitted.

By submitting the manuscript to Gujarat Cancer Society Research Journal, the authors agree that the work is original and free from plagiarism. It has not been submitted for publication/ is not under consideration for publication at another Journal. The journal expects that authors would authorize one of them to correspond with the journal for all matters related to the manuscript. The email address of corresponding author should be provided.

“Contributors Form” will be available on journal website www.gcriindia.org GCS Research Journal, Volume 22 Number 1 April 2020 should be downloaded duly signed by all contributors of manuscript/case report and submitted along with the hard copy to journal office.

Manuscript Format

Manuscript submitted using Microsoft Word, Font Times Roman, Paper size A4, Margin 2.5 cm from all four sides for Windows is preferred. Images should be submitted as JPEG file. Manuscripts reporting clinical studies should, where appropriate, contain a statement that they have been carried out with ethical committee approval.

All manuscripts should include the following sections, in order. All sections are mandatory unless designated "optional":

- Title page
- Summary
- Main text
- Abbreviations
- Acknowledgements (optional)
- Contributions (optional)
- Competing interests
- References
- Tables
- Figures

Types & size of Manuscripts

1. Original article: The text of original articles amounting to up to 3000 words (excluding summary, references and tables) should be divided into sections with the headings summary (unstructured - max. 200 words), Key-words, Introduction, Material and Methods, Results, Discussion, Conclusion, References (max. up to 25), Tables and Figure legends.

2. Case report: It should have maximum limit up to 1000 words (excluding summary and references) and should have the following headings: summary (unstructured - max. 200 words), Keywords, Introduction, Case report, Discussion, Reference (max. up to 10), Table and Figure legends.

3. Review article: It should have summary (max. 200 words), Introduction/Historical Background, Discussion, Conclusion, References, Tables and Figure Legends.

4. Short communication: The length of it should not exceed 1000 words and References 10.

Note: Discussion and conclusion can be combined in one section. Please do not add numbers before subtitles. Write subtitles and headings in sentence case.

Title Page

Include in the title page the manuscript title, author’s name(s), affiliations, and corresponding author’s phone/fax number and/or email. The name of the department(s) and institution(s) to which the work should be attributed

Title: Use sentence format; only the first word and proper nouns should be capitalized.
Results

Provide a concise and precise description of the only important observations of experimental results, their interpretation as well as the conclusions that can be drawn. Do not repeat in the text all the data in the Tables, and Figures. Restrict Tables and Figures to those needed to explain the argument of the paper and to assess its support. Avoid duplication and repetition of data in Figures and Tables. Specify the statistical methods used to analyze the data.

Discussion

Authors should discuss the results and how they can be interpreted in perspective of previous studies and of the working hypotheses. The findings and their implications should be discussed in the broadest context possible and limitations of the work highlighted. Future research directions may also be mentioned. This section may be combined with results.

Conclusions

This section is not mandatory, but can be added to the discussion.

Tables (Font size: 12)

Type each Table double-spaced on a separate sheet. Number Tables consecutively in Arabic numerals (e.g. 1, 2, 3) in the order of their first citation in the text and supply a brief title, which should be shown at the top of each table.

Figures and Legends

All Figures must be submitted on separate sheet, in JPEG finished format that is ready for reproduction. Figures should be numbered consecutively in Arabic numerals (e.g. Figure 1, 2, 3) according to the order in which they have been first cited in the text. If photographs of persons are used, the subjects or patients must not be identifiable.

Legends

Present the legends for Figures on separate sheet (Font size: 12) using double-spacing with Arabic numerals corresponding to the Figures.

Acknowledgements (Font size: 9)

State contributions that need to be acknowledged.

References (Font size: 12):

References on separate sheet and must be numbered in order of appearance in the text. Identify references in the text in numerals in superscript and parenthesis. Omit month and issue number. List all authors, but if the number is six or more, list first three followed by et al. The references should be cited
according to the Vancouver agreement (International Committee of Medical Journal Editors). Authors must check and ensure the accuracy of all references cited. Abbreviations of titles of medical periodicals should conform to the latest edition of Index Medicus. Some examples are shown below:

**Standard Journal**

**Online Journal Article**

**Chapter in a Book**

**Online Book or Website**

**In Press**

**Referees**
Generally, submitted manuscripts are sent to two experienced referee from our panel. The contributor’s may submit names of two to five qualified reviewers who have had experience in the subject of the submitted manuscript, but not associated with the same institution(s) as contributors nor have published manuscripts with the contributors in the past 10 years.
Contributors' Form

(to be modified as applicable and one signed copy attached with the manuscript)

Journal Title:
Manuscript Title:
Manuscript type: Original article / Review article / case report / short communication / letter to editor
Manuscript Number:

I/we certify that
1. I/we have participated sufficiently in contributing to the intellectual content, concept and design of this work or the analysis and interpretation of the data (when applicable), as well as preparation of the manuscript, to take public responsibility for it and have agreed to have my/our name listed as a contributor.

2. We surrender the rights to the corresponding author to make necessary changes as per the request of the journal, do the rest of the correspondence on our behalf and he/she will act as the guarantor for the manuscript on our behalf.

3. The manuscript is original work or compilation, without fabrication, plagiarism and fraud.

4. The manuscript neither is currently under consideration elsewhere nor will be submitted elsewhere for publication unless a final decision is made by Editors of journal as it is not acceptable

<table>
<thead>
<tr>
<th>Name</th>
<th>Signature</th>
<th>Date signed</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Up to 4 contributors for case report/ short communication / review)

<table>
<thead>
<tr>
<th>Name</th>
<th>Signature</th>
<th>Date signed</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Up to 6 contributors for original studies)

Corresponding author: ________________________________
Mailing address: ____________________________________________

Phone: ________________________________ Email: ________
Guidelines for Reviewers

The unpublished manuscript under peer review is a privileged document. Reviewers are expected not to cite a manuscript or refer to the work it describes before it has been published, and to refrain from using the information it contains for the advancement of their own research.

Reviewers are requested to help authors improve their manuscript. The report should give constructive analysis to authors, particularly where revisions are recommended. Where reviewers do not wish authors to see certain comments, these can be added to the confidential comments to the Editor column in peer review sheet.

Suggested revisions should be couched as such and not expressed as conditions for acceptance. Please distinguish between revisions considered essentials and those merely desirable.

The editor gratefully receives a reviewer’s recommendations, nonetheless the editorial decisions are usually based on evolutions derived from several sources, a reviewer should not expect the editor to honors his or her every recommendation.

**Reviewers should consider the following core aspects on the manuscript as far as applicable:**

- Importance (clinical or otherwise) of the question or subject studied
- Scientific reliability?
- Originality (truly original or known to you through foreign or specialist publications or through the grapevine)
- Adequacy of summary, key words.
- Patients (sample size) studied, adequately described and their condition defined?
- Appropriateness of approach or experimental design, adequacy of experimental techniques (including statistics where appropriate, need for statically assessment).
- Methods adequately described?
- Results relevant to problem posed? Credible? Well presented?
- Soundness of conclusions and interpretation. Interpretation and conclusions warranted by the data? Reasonable speculation? Is the message clear?
- Relevance of discussion
- References up to date and relevant? Any glaring omissions?
- Relevance of the figures and table, clarity of legends and titles.
- Suitability for the journal and overall recommendations. Appropriate for general readerships or more appropriate for specialist journal?
- If not acceptable can the paper be made acceptable?
- Ethical aspects
- Overall presentation (including writing style, clarity of writing)
Cancer is now considered as Genetic Disease meaning that cancer is caused by certain changes to genes that control the cells function, especially how they grow and divide. Certain gene changes can cause cells to evade normal growth controls and transform into cancer. Some cancer-causing gene changes increase production of a protein that makes cells grow. The genetic changes are of two types, germline changes and somatic changes. Genetic changes that promote cancer can be inherited from parents to offspring called germline changes. Cancer-causing genetic changes can also be acquired during one’s lifetime, as the result of errors that occur as cells divide or from exposure to carcinogenic substances that damage DNA, such as certain chemicals in tobacco smoke and chewing tobacco, and radiation, such as ultraviolet rays from the sun. Genetic changes that occur after conception are called somatic (or acquired) changes.

These gene mutations can be identified in DNA and RNA of an individual by Next Generation Sequencing (NGS). DNA or RNA sequencing tests can “read” DNA or RNA, respectively. By comparing the sequence of DNA or RNA in cancer cells with that in normal cells, identify genetic changes in cancer cells that may be driving the growth of an individual’s cancer. This information will help to predict which therapies might work best against a particular tumor.

Currently, cancer treatment decisions are increasingly made on the basis of genomic information, and there are currently large numbers of genomic tests available to oncologists. Genomic tests designed to facilitate decisions about treatment management include those that identify alterations in single genes and multimarker tumor panels. Multigene panels include targeted gene-expression profiling tests that are used to estimate prognosis and/or the likelihood of recurrence. Multimarker panels also include DNA and RNA analysis through NGS technologies, including custom panels that profile multiple actionable driver genes, fusion genes and tumor characteristics that may guide the selection of targeted therapies.

Hence, NGS is of utmost requirement for identification of gene mutations in various cancers as well as in hereditary cancers for identification of family members at risk of cancer.

There are disease specific Multigene-Cancer Panels available that analyze number of genes associated with hereditary and sporadic cancers across major organ systems, including:

- breast and gynecologic (breast, ovarian, uterine)
- gastrointestinal (colorectal, gastric, pancreatic)
- endocrine (thyroid, paraganglioma/pheochromocytoma, parathyroid, pituitary)
- genitourinary (renal/urinary tract, prostate)
- skin (melanoma, basal cell carcinoma)
- brain/nervous system
- sarcoma
- hematologic(myelodysplastic syndrome/leukemia)

The Multigene-Cancer Panel is designed to maximize diagnostic yield for individuals with a personal or family history of mixed cancers affecting multiple organ systems.

Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives.

Recently, Next Generation Sequencing (NGS) facility: The Ion Torrent™ Genexus Integrated Sequencer and Ion GeneStudio S5 system (ThermoFisher Scientific) is established at the Cancer Biology Department, GCRI.

The Genexus Integrated Sequencer - Ion Torrent is the first turnkey next-generation sequencing (NGS) solution that automates all steps of the targeted NGS workflow starting from Nucleic Acid to results. The Nucleic Acid to Result workflow starts from purified and quantified nucleic acid
samples. Purified nucleic acid samples are pipet into a 96-well sample input plate and then loaded into the Genexus™ Integrated Sequencer for library preparation, templating, and sequencing. With a single touchpoint and five minutes of hands-on time, the Genexus sequencer automates NGS library preparation (including cDNA synthesis), template preparation, sequencing, primary data analysis, and variant reporting for DNA, RNA, and cDNA applications. Sequencing on the Genexus sequencer is done on a four-lane semiconductor chip: the Ion Torrent GX5 Chip. Each of the four lanes of the GX5 Chip supports the output of 12–15 million reads, and they can be used individually or all at once depending on throughput needs. Ion Torrent Genexus Software streamlines the NGS workflow by integrating the setup-to-report workflow within a single software ecosystem.

The Ion GeneStudio S5 system is designed to enable a broad range of targeted next-generation sequencing (NGS) applications with speed and scalability. Five Ion S5 chips (Ion 550 chip, Ion 540 chip, Ion 530 chip, Ion 520 chip and Ion 510 chip) enable a sequencing throughput range of 2M to 130M reads per run.

During standardization on NGS, eight samples of each DNA and RNA of AML patients were sequenced using the Ion Torrent Oncomine Myeloid Assay GX v2 by Molecular Diagnostics & Research Lab-2 (MDRL-2). Moreover, DNA and RNA samples of four lung carcinoma and four brain tumor patients were sequenced and analyzed using the Oncomine Precision Assay (OPA) by MDRL-3 and MDRL-1 of Cancer Biology Department, respectively.

Table 1: Gene content of the Oncomine Myeloid Assay GX v2 panel

<table>
<thead>
<tr>
<th>Hotspot genes (28)</th>
<th>Full genes (17)</th>
<th>Fusion driver genes (35)</th>
<th>Expression genes (5)</th>
<th>Expression control genes (5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANKRD2</td>
<td>KRAS</td>
<td>ABL1</td>
<td>HMGA2</td>
<td>NUP214</td>
</tr>
<tr>
<td>6 ABL1</td>
<td>MASP3</td>
<td>ABL2</td>
<td>JAK2</td>
<td>BAALC</td>
</tr>
<tr>
<td>BRAF</td>
<td>MYD88</td>
<td>BCL2</td>
<td>KAT6A</td>
<td>MECOM</td>
</tr>
<tr>
<td>CBL</td>
<td>NPM1</td>
<td>BRAF</td>
<td>KAT6B</td>
<td>MYC</td>
</tr>
<tr>
<td>CSF3R</td>
<td>NRAS</td>
<td>CCND1</td>
<td>KMT2A</td>
<td>SMC1A</td>
</tr>
<tr>
<td>DDX4I</td>
<td>PPM1D</td>
<td>CREBBP</td>
<td>KMT2A-PTD</td>
<td>SMC1A</td>
</tr>
<tr>
<td>DNM1</td>
<td>PTPN1</td>
<td>EGFRI</td>
<td>MLLT10</td>
<td>MLC1A</td>
</tr>
<tr>
<td>A FLT3 (ITD +</td>
<td>SMC1A</td>
<td>ETF6</td>
<td>MRTFA</td>
<td>NUP98</td>
</tr>
<tr>
<td>TKD)</td>
<td>SETBP1</td>
<td>EGFRI</td>
<td>(MKL1)</td>
<td>PAX5</td>
</tr>
<tr>
<td>GATA2</td>
<td>SF3B1</td>
<td>FGFR1</td>
<td>MECOM</td>
<td>PDGFR</td>
</tr>
<tr>
<td>HRAS</td>
<td>SRSF2</td>
<td>FGFR2</td>
<td>MET</td>
<td>PDGFRB</td>
</tr>
<tr>
<td>IDH1</td>
<td>U2AF1</td>
<td>FUS</td>
<td>MLL1</td>
<td>RARA</td>
</tr>
<tr>
<td>IDH2</td>
<td></td>
<td></td>
<td></td>
<td>RUNX1</td>
</tr>
<tr>
<td>JAK2</td>
<td></td>
<td></td>
<td></td>
<td>TCF3</td>
</tr>
<tr>
<td>KIT</td>
<td></td>
<td></td>
<td></td>
<td>TFE3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ZNF384</td>
</tr>
</tbody>
</table>

Ion Torrent Oncomine Myeloid Assay GX v2

The Ion Torrent Oncomine Myeloid Assay GX v2 is a comprehensive targeted next-generation sequencing (NGS) assay designed for sensitive detection of myeloid disorder-associated DNA mutations and RNA fusion transcripts in blood and bone marrow samples. This assay is compatible with the Genexus Integrated Sequencer, which performs library preparation, sequencing, analysis, and reporting in an automated sample-to-result workflow. Depending on the workflow, results can be obtained in as little as a single day.

Oncomine Myeloid Assay GX v2 features include:

- Comprehensive coverage of key DNA mutations and >700 fusion transcripts associated with myeloid disorders
- Automated sample-to-report workflow on the Genexus sequencer in less than a day
- Sequencing of up to eight samples (DNA & RNA) per lane on a GX5 Chip in a single run
- Less than 15 minutes hands-on time
- Detection of somatic variants down to 5% allele frequency

With the Oncomine Myeloid Assay GX v2, 45 DNA target genes and 35 RNA fusion driver genes can be interrogated simultaneously, covering the most relevant targets associated with major myeloid disorders, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) (Table 1).
This multiplex primer design leverages Ion AmpliSeq technology to generate results from multiple samples in a single run. Sequencing results are automatically analyzed by Genexus software using an optimized assay-specific analysis workflow.

**Oncomine Precision Assay**

The Oncomine Precision Assay enables simultaneous detection of biomarkers across 50 genes, including key targets within EGFR, BRAF, KRAS, ALK, ROS1, NTRK, RET, and others, from both solid tissue and liquid biopsy samples. (Figure 1) The kit provides a targeted pan-cancer panel and library reagents sufficient to perform up to 32 sequencing reactions on the Ion Torrent Genexus Integrated Sequencer using the Ion Torrent GX5 Chip.

When used with the Oncomine Precision Assay, the Genexus Integrated Sequencer performs library preparation, sequencing, analysis, and reporting in an automated sample-to-result workflow that delivers results in as little as a single day. Moreover, the Oncomine Precision Assay, based on Ion Torrent™ AmpliSeq™ HD technology, requires only 10 ng of DNA or RNA, resulting in more than 95% of samples producing sequencing results.

**Minimum sample input and maximum sample success rate**

Key benefits of the Oncomine Precision Assay on the integrated Genexus System all operated by one Ion

---

**Figure 1: Oncomine Precision Assay content**

**Table 2: Results of Oncomine Myeloid assay GX v2**

<table>
<thead>
<tr>
<th>Patients</th>
<th>RNA</th>
<th>DNA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CNV</td>
<td>Fusion</td>
</tr>
<tr>
<td>Patient 1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Patient 2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PTPN11</td>
</tr>
<tr>
<td>Patient 3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NPM1</td>
</tr>
<tr>
<td>Patient 4</td>
<td>-</td>
<td>PML(6)-RARA(3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NPM1</td>
</tr>
<tr>
<td>Patient 5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Patient 6</td>
<td>-</td>
<td>PML(6)- RARA(3)</td>
</tr>
<tr>
<td>Patient 7</td>
<td>-</td>
<td>BCR(13)-ABL1(2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NPM1</td>
</tr>
<tr>
<td>Patient 8</td>
<td>BCR(13)-ABL1(2)</td>
<td>IDH2</td>
</tr>
</tbody>
</table>
### Table 3: Results of Oncomine Precision Assay (OPA)

<table>
<thead>
<tr>
<th>Patients</th>
<th>Cancer site</th>
<th>DNA</th>
<th>RNA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CNV</td>
<td>SNV / Indels</td>
</tr>
<tr>
<td>Gene</td>
<td>Type of mutation</td>
<td>Gene</td>
<td>Type of mutation</td>
</tr>
<tr>
<td>Patient 1</td>
<td>Brain</td>
<td>-</td>
<td>TP53, FLT3, IDH1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hotspot- Loss of function</td>
<td>Hotspot- Gain of function</td>
</tr>
<tr>
<td>Patient 2</td>
<td>Brain</td>
<td>IDH1</td>
<td>Hotspot- Gain of function</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALAS1</td>
<td>ANKRD17, AR, EIF2B1, FGFR3 G6PD, HMBS, MET, TBP</td>
</tr>
<tr>
<td>Patient 3</td>
<td>Brain</td>
<td>AR, FLT3, IDH2, NTRK1</td>
<td>Hotspot- Gain of function</td>
</tr>
<tr>
<td>Patient 4</td>
<td>Brain</td>
<td>EGFR, FLT3, IDH1</td>
<td>Hotspot- Gain of function</td>
</tr>
<tr>
<td>Patient 5</td>
<td>Lung</td>
<td>EGFR</td>
<td>Hotspot- Gain of function</td>
</tr>
<tr>
<td>Patient 6</td>
<td>Lung</td>
<td>HRAS, TP53</td>
<td>Hotspot- Gain of function</td>
</tr>
<tr>
<td>Patient 7</td>
<td>Lung</td>
<td>EGFR</td>
<td>Hotspot- Gain of function</td>
</tr>
<tr>
<td>Patient 8</td>
<td>Lung</td>
<td>AR, EGFR, Tp53</td>
<td>Exon 9 deletion- Gain of Function</td>
</tr>
</tbody>
</table>

### Table 4: Oncomine Assays and Panels compatible with Genexus Integrated Sequencer and Ion GeneStudio S5 system

<table>
<thead>
<tr>
<th>Genexus</th>
<th>S5 Sequencer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncomine Precision Assay Plus – 500 genes panel includes TMB, MSI</td>
<td>Oncomine Precision Assay Plus – 500 genes panel includes TMB, MSI</td>
</tr>
<tr>
<td>Oncomine Precision Assay – 50 genes panel</td>
<td>Oncomine Precision Assay – 50 genes panel</td>
</tr>
<tr>
<td>Oncomine Focus Assay – 52 genes panel</td>
<td>Oncomine Focus Assay – 52 genes panel</td>
</tr>
<tr>
<td>Oncomine Comprehensive Assay v3 – 161 genes panel</td>
<td>Oncomine Comprehensive Assay v3 – 161 genes panel</td>
</tr>
<tr>
<td>15-30 genes panel</td>
<td>Oncomine Bladder Panel</td>
</tr>
<tr>
<td>Oncomine BRCA Panel</td>
<td>Oncomine BRCA Extended Panel</td>
</tr>
<tr>
<td>Oncomine CRC and Pancreatic Panel</td>
<td>Oncomine CRC and Pancreatic Panel</td>
</tr>
<tr>
<td>Oncomine Gastric &amp; Esophageal Panel</td>
<td>Oncomine Gastric &amp; Esophageal Panel</td>
</tr>
<tr>
<td>Oncomine Gynecological Panel</td>
<td>Oncomine Gynecological Panel</td>
</tr>
<tr>
<td>Oncomine Kidney Panel</td>
<td>Oncomine Kidney Panel</td>
</tr>
<tr>
<td>Oncomine Liver Panel</td>
<td>Oncomine Liver Panel</td>
</tr>
<tr>
<td>Oncomine Lymphoma Panel</td>
<td>Oncomine Lymphoma Panel</td>
</tr>
<tr>
<td>Oncomine Melanoma Panel</td>
<td>Oncomine Melanoma Panel</td>
</tr>
<tr>
<td>Oncomine Prostate Panel</td>
<td>Oncomine Prostate Panel</td>
</tr>
<tr>
<td>Oncomine Myeloid Assay</td>
<td>Oncomine Myeloid Assay</td>
</tr>
<tr>
<td>Oncomine cfDNA Assay</td>
<td>Oncomine cfDNA Assay</td>
</tr>
<tr>
<td>Oncomine Tumor Mutation Load Assay</td>
<td>Oncomine Tumor Mutation Load Assay</td>
</tr>
<tr>
<td>HLA Sequencing</td>
<td>HLA Sequencing</td>
</tr>
</tbody>
</table>

Gujarat Cancer Society Research Journal

Volume 24 Number 2 October 2022 31
curated to include all potentially relevant targets of emerging importance for fast genomic profiling in clinical cancer research.

The results of Ion Torrent Oncomine Myeloid Assay GX v2 and the Oncomine Precision Assay (OPA) are shown in Table 2 and Table 3, respectively.

Apart from these, there are multimarker panels for different malignancies that are compatible with Genexus Integrated Sequencer and Ion GeneStudio S5 system (Table 4).

The NGS facility is installed with the help of Corporate Social Responsibility (CSR) of Gujarat Government.

Figure 2 and 3 show the representative images of results for Oncomine Precision Assay (OPA) and Oncomine Myeloid assay GX v2, respectively by Ion Torrent Genexus Software.

---

**Variant Report**

**Oncomine Precision - GX5 - Solid Tumor - DNA and Fusions - w3.2.0**

<table>
<thead>
<tr>
<th>Cancer Type:</th>
<th>Glioblastoma</th>
<th>Date: 22 Sep 2022</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Sample Details</th>
<th>Sample Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample Name:</td>
<td>Brain-3</td>
</tr>
<tr>
<td>Application Category:</td>
<td>Solid Tumor</td>
</tr>
<tr>
<td>Sample Type:</td>
<td>DNA &amp; RNA</td>
</tr>
<tr>
<td>Cancer Type:</td>
<td>Glioblastoma</td>
</tr>
<tr>
<td>Cancer Stage:</td>
<td>Unknown</td>
</tr>
<tr>
<td>Collection Date:</td>
<td>20 SEP 2022</td>
</tr>
<tr>
<td>Gender:</td>
<td>Unknown</td>
</tr>
<tr>
<td>%Cellularity:</td>
<td>50</td>
</tr>
<tr>
<td>%Necrosis:</td>
<td></td>
</tr>
</tbody>
</table>

**Results for Sequence Variations Detected**

**SNVs/indels**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant ID</th>
<th>Oncomine Variant Class</th>
<th>Oncomine Gene Class</th>
<th>AA Change</th>
<th>Call</th>
<th>Allele Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLJ3</td>
<td>COSM785</td>
<td>Hotspot</td>
<td>Gain of Function</td>
<td>p.D835H</td>
<td>PRESENT (HETERO ZYGOS)</td>
<td>0.311</td>
</tr>
<tr>
<td>IDH2</td>
<td>COSM33733</td>
<td>Hotspot</td>
<td>Gain of Function</td>
<td>p.R172K</td>
<td>PRESENT (HETERO ZYGOS)</td>
<td>0.423</td>
</tr>
<tr>
<td>NTBK1</td>
<td>BT104</td>
<td>Hotspot</td>
<td>Gain of Function</td>
<td>p.V573M</td>
<td>PRESENT (HETERO ZYGOS)</td>
<td>0.041</td>
</tr>
</tbody>
</table>

**Fusions**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant ID</th>
<th>Oncomine Variant Class</th>
<th>Oncomine Gene Class</th>
<th>Type</th>
<th>Call</th>
<th>Read Counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESR1</td>
<td>ESR1-CCDC170L.E2</td>
<td>Fusion</td>
<td>Gain of Function</td>
<td>Fusion</td>
<td>PRESENT</td>
<td>41</td>
</tr>
<tr>
<td>FGFR1</td>
<td>BAG4-FGFR1.B1F2</td>
<td>Fusion</td>
<td>Gain of Function</td>
<td>Fusion</td>
<td>PRESENT</td>
<td>26</td>
</tr>
</tbody>
</table>

**CNVs**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Oncomine Variant Class</th>
<th>Oncomine Gene Class</th>
<th>Call</th>
<th>Copy Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>AR</td>
<td></td>
<td></td>
<td>PRESENT (LOSS)</td>
<td>0.98</td>
</tr>
</tbody>
</table>

**Figure 2:** Ion Torrent Genexus Software results for Oncomine Precision Assay (OPA)
## Variant Report

**Oncomine Myeloid - GX5 - DNA and Fusions - w4.2.2**

Cancer Type: Myoepithelial Carcinoma  
Date: 17 Sep 2022

### Results for Sequence Variations Detected

<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant ID</th>
<th>Oncomine Variant Class</th>
<th>Oncomine Gene Class</th>
<th>AA Change</th>
<th>Call</th>
<th>Allele Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Arg666_Gln695dup</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.022</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Val952_Glu958Asp959Ser</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.035</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Glu596_Thr599Asp600Asp601Glu</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Tyr972_Glu978Asp980Thr</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.211</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Glu596_Thr599Asp600Asp601Glu</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Glu596_Thr599Asp600Asp601Glu</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.077</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Glu596_Thr599Asp600Asp601Glu</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.074</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Leu601_Lys602Asp603Glu</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Tyr597_Glu598Asp599Glu</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.204</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>-</td>
<td>Gain-of-Function</td>
<td>p.Arg968_Glu981Asp982Asp983Glu</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.009</td>
<td></td>
</tr>
<tr>
<td>W11</td>
<td>-</td>
<td>Truncating</td>
<td>p.Leu238GlyfsTer11</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.095</td>
<td></td>
</tr>
<tr>
<td>W11</td>
<td>-</td>
<td>Truncating</td>
<td>p.Arg778SerfsTer8</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.353</td>
<td></td>
</tr>
<tr>
<td>W11</td>
<td>COSM27309</td>
<td>Truncating</td>
<td>p.Ser383fsTer71</td>
<td>PRESENT (HETERO ZYGODUS)</td>
<td>0.477</td>
<td></td>
</tr>
</tbody>
</table>

### Fusions

None Detected

### CNVs

None Detected

---

**Figure 3:** Ion Torrent Genexus Software results for Oncomine Myeloid assay GX v2
THE GUJARAT CANCER SOCIETY
OFFICE BEARERS 2021-2022

Vice Presidents
Health Minister Govt. of Gujarat
Padma Shree Dr. Pankaj M. Shah
Shri Kshitish Madanmohan
Shri Chintan Parikh
Smt. Bhartiben Parikh

President
Hon'ble Governor Shri of Gujarat
Shri Acharyya Devvrat

Executive Chairman and
Vice President
Shri Pankaj R. Patel

Trustees
Shri Pankaj R. Patel
Shri Prashant Kinarivala
Shri Kshitish Madanmohan
Shri Rajesh Jaykrishna
Shri Navnit Choksi

General Secretary
Shri Prashant Kinarivala

Secretaries
Shri Kaushik Patel
Shri Deevyesh Radia

Treasurers
CA Bipin M. Shah

Members of Governing Board - GCRI
Shri Pankaj R. Patel
Chairman

Nominated by
Govt. of Gujarat
Shri Manoj Aggarwal, IAS
ACS, Health & Family Welfare Dept.
Govt. of Gujarat
Dr. Rajiv Kumar Gupta, IAS
Chairman, GMDC
ACS, Industries & Mines Dept.
Govt. of Gujarat
Smt. Shahmeena Husain, IAS
Commissioner of Health, Medical Services
& Medical Education, Govt. of Gujarat
Ms. Manisha Chandra, IAS
Secretary, Finance Dept. (Expenditure)
Govt. of Gujarat
Dr. Bharat Amin
Consultant Surgeon

Nominated by
Govt. of India
Deputy Director General
Directorate General of Health Services,
Ministry of Health & Family Welfare,
New Delhi
Director (IF)
Ministry of Health & Family Welfare
Govt. of India, New Delhi

Nominated by
Gujarat Cancer Society
Shri Pankaj R. Patel
Executive Chairman, GCS
Shri Prashant Kinarivala
General Secretary, GCS
Shri Kshitish Madanmohan
Vice President, GCS
Shri Chintan Parikh
Vice President, GCS

Director, GCRI
Dr. Shashank J. Pandya

I/C Dy. Director, GCRI
Dr. Priti Sanghavi

Past Director
Dr. Shilin N Shukla

Director, GCSMCH & RC
Dr. Kirti M Patel

CEO, COC, Vasna
Dr. Geeta Joshi

Representative of Donors
Aditya Choksi
Ajit C. Mehta
Amrish Parikh
Bharatkumar C. Kshatriya
Brijmohan Chetram Kshatriya
Chandravadan R Patel
Dilip Sarkar
Dr. Nitin Sumant Shah

Dr. Rajendra I. Dave
Gokul M. Jaikrishan
Janak Dipakbhai Parikh
Jayshreebhen Lalbhai
Kandarp Kinarivala
Kanubhai Patel
Kshamaben Nagar
Nitin S Parikh
Piyushbhai Desai

Pradip Kamdar
Prakashbhai Bhagwati
Pratima Desai
President, Punjabi Seva Samaj
Rina Bhagwati
Sandip Engineer
Shefaliben Parikh
Shubhang Madanmohan
Sudhir Nanavati

Medical Members
Additional Director, Medical Education & Research, Govt. of Gujarat

Dean, B. J. Medical College
Director, Post Graduate studies
Director, U.N. Mehta Institute of Cardiology

Dean, Govt. Dental College
Principal, Nursing School
Dr. Premal Thakore
Dr. Rajendra Dave

Medical Superintendent,
Civil Hospital
Director, N. I. O. H.
Padma Shree Dr. Devenrda D. Patel
2021 - 2022
THE GUJARAT CANCER & RESEARCH INSTITUTE
SCIENTIFIC RESEARCH COMMITTEE

Chairman
Dr. Shashank J. Pandya
Co-Chairperson
Dr. Pariseema Dave
Dr. Priti Sanghavi
Assistant Member Secretary
Dr. Sonia Parikh
Dr. Hemangini Vora

Members
Dr. Kirti Patel (External)
Dr. Shilin Shukla
Dr. Sunil Trivedi (External)
Dr. Prabhambhai Patel (External)
Dr. Rakesh Rawal (External)
Dr. U. Suryanarayan
Dr. Shilpa Patel
Dr. Foram Patel
Dr. Priti Trivedi
Dr. Jayshree Thakkar

Members
Dr. Nandita Ghosh
Dr. Trupti Trivedi
Dr. Jayendra Patel
Dr. Franky Shah
Dr. Pina Trivedi

GCRI - GCS ETHICS COMMITTEE
Chairman
Hon'ble Justice Shri Bankim N Mehta
Vice Chairman
Shri Milan Narayanbhai Patel
Member Secretary
Dr. Pariseema Dave
Alternate Member Secretary
Dr. Hemangini Vora
Members
Shri Kshitish Madanmohan
Dr. R K Dikshit
Dr. Amar Vyas
Dr. Sonia Parikh
Dr. Vishal Mishra
Mrs. Ila U Vora
Ms. Nuri Kalita

Institutional Review Committee for
Dissertation / Thesis / Publications / Conference Presentations
Chairperson
Dr. Shashank J. Pandya
Co-Chairperson
Dr. Pariseema Dave
Member Secretary
Dr. Harsha Panchal
Dr. Trupti Trivedi
Members
Mr. Kshitish Madanmohan
(NGO representative, Social Worker)
Dr. Amar Vyas (Social Worker) (External)
Dr. Prabhambhai S. Patel (External)
Dr. U. Suryanarayan
Dr. Priti Sanghvi
Dr. Hemangini Vora
Dr. Himanshu Soni
Dr. Trupti Patel
Dr. Foram Patel
Dr. Franky Shah
Cancer Biology Department

Genexus Integrated Sequencer

Ion GeneStudio S5